We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




New Test Reveals Existing Antibiotics Can Cure Superbugs

By LabMedica International staff writers
Posted on 02 May 2023

A new test has revealed that FDA-approved antibiotics, readily available at local pharmacies, can effectively combat superbugs. These antibiotics are not prescribed due to the gold-standard test indicating their inefficacy. This novel test could revolutionize the development, testing, and prescription of antibiotics, playing a crucial role in the battle against bacterial resistance by optimizing the use of existing antibiotics and bolstering the search for new ones.

The antibiotic study by a team of scientists at UC Santa Barbara (Santa Barbara, CA, USA) tackled a fundamental issue in the current healthcare approach to determining antibiotic resistance, which fails to consider the environmental conditions within the body that influence drug efficacy. By replicating these conditions, the new test pinpointed several effective antibiotics that standard testing had dismissed. When both the new and standard tests concurred, a near-perfect prediction of treatment success or failure emerged. The study involved extensive screening of over 500 antibiotic-bacteria combinations, with the findings indicating that the standard test is inaccurate approximately 15% of the time. Since doctors depend on this test to guide treatment decisions, it may result in the prescription of inappropriate antibiotics.

Medical professionals are aware of the gold-standard test's limitations. When the suggested antibiotics prove ineffective, physicians must draw upon their experience to determine the most suitable antibiotic(s) for their patients. This study offers a potential solution to bridge the gap between the antibiotics suggested by standard testing and actual patient outcomes. The new test could lead to substantial cost savings for the healthcare sector as they endeavor to identify novel drugs to combat antimicrobial-resistant infections.

“Reevaluation of FDA-approved antibiotics may be of far greater benefit than the time and cost of developing new drugs to combat antimicrobial resistance,” explained Santa Barbara Cottage Hospital physician Lynn Fitzgibbons, M.D., “potentially leading to significant life-savings and cost-savings.”

Related Links:
UC Santa Barbara 

Gold Member
Veterinary Hematology Analyzer
Exigo H400
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Malaria Test
STANDARD Q Malaria P.f/Pan Ag
New
Biological Indicator Vials
BI-O.K.
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get complete access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The experimental blood test accurately indicates severity and predicts potential recovery from spinal cord injury (Photo courtesy of 123RF)

Blood Test Identifies Multiple Biomarkers for Rapid Diagnosis of Spinal Cord Injury

The National Institutes of Health estimates that 18,000 individuals in the United States sustain spinal cord injuries (SCIs) annually, resulting in a staggering financial burden of over USD 9.... Read more

Immunology

view channel
Image: The findings were based on patients from the ADAURA clinical trial of the targeted therapy osimertinib for patients with NSCLC with EGFR-activated mutations (Photo courtesy of YSM Multimedia Team)

Post-Treatment Blood Test Could Inform Future Cancer Therapy Decisions

In the ongoing advancement of personalized medicine, a new study has provided evidence supporting the use of a tool that detects cancer-derived molecules in the blood of lung cancer patients years after... Read more

Industry

view channel
Image: Tumor-associated macrophages visualized using the Multiomic LS Assay (Photo courtesy of ACD)

Leica Biosystems and Bio-Techne Expand Spatial Multiomic Collaboration

Bio-Techne Corporation (Minneapolis, MN, USA) has expanded the longstanding partnership between its spatial biology brand, Advanced Cell Diagnostics (ACD, Newark, CA, USA), and Leica Biosystems (Nussloch,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.